Ascendia

25 Year BadgeDrug Development & Delivery Celebrates 25 Years!

For a quarter century, Drug Development & Delivery has connected innovators, scientists, and industry leaders while spotlighting the technologies and ideas shaping the future of the industry. We celebrate 25 years of advancing the conversation!

  MARKET NEWS

AI Failures Cost Life Sciences Organizations Millions as Process Gaps Persist
Zeteo Biomedical Takes Active Powder Delivery Platform Into Pulmonary Market
Novo Nordisk Launches ‘Novo’ Rebrand to Sharpen Global Identity
New Hovione Facility Expands U.S. Capacity for Poorly Soluble Drug Development
Upperton Secures MHRA Approval for New Sterile Manufacturing Facility

  EXPERT CONTENT & RESOURCES

 

FROM ASSESSMENT TO SUSTAINABLE ACTION - Circular Economy Strategies & Practical Routes to Lower-Impact Medical Devices

FROM ASSESSMENT TO SUSTAINABLE ACTION - Circular Economy Strategies & Practical Routes to Lower-Impact Medical Devices

AstraZeneca and Novo Nordisk have both committed to science-based net-zero across their full value chains by 2045. However, decarbonizing manufacturing alone leaves most of the footprint untouched. Meeting these net-zero targets requires changes to the products themselves, the devices that deliver them, and the systems built around them, including the reprocessing and reuse networks. The route to a more sustainable device is not the same for every product, and the single biggest determinant of what is achievable is where a device sits in its product development lifecycle when sustainability is first considered.

John Jansen

Managing Fragmented Small-Molecule Supply Chains Through Strategic Secondary Bulk Packaging

As small-molecule manufacturing becomes increasingly fragmented across regions, specialist facilities, and CDMOs, every product handoff introduces new opportunities for delay and variability. A strategic bulk secondary packaging approach can help standardize product handling, improve operational control, and strengthen resilience across complex pharmaceutical supply chains.

Abbvie Logo

Four Myths About Embedded CMOs, Busted

Are your perceptions of the CMO marketplace serving your drug program—or holding it back? If you’re looking for a contract manufacturer to bring your therapy to market, you’re far from alone. Demand for manufacturing services is shaping the pharma Contract Manufacturing Industry, with analysts predicting a growth rate of nearly 7% per year until 2028. In such a competitive market, how should a project sponsor navigate the choice between one CMO and another? To find the answer, many sponsors begin by distinguishing between typical stand-alone CMOs and an embedded CMO that operates under a parent company—AbbVie, in the case of AbbVie Contract Manufacturing (AbbVie).

  FEATURED EDITORIAL

  EXPERT INSIGHTS VIDEOS

The Future of Injection Devices: Key Trends Shaping Drug Delivery

The Future of Injection Devices: Key Trends Shaping Drug Delivery

  COMPANY PROFILE

Adare Pharma Solutions is a global technology-driven contract development and manufacturing organization (CDMO) providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with small molecule expertise focusing on oral dosage forms for the pharmaceutical industry. Adare’s specialized technology platforms provide taste masking, customized release, multiparticulate systems, and patient-centric dosing solutions. With a proven history in drug delivery, Adare’s facilities in the U.S. and Europe have developed and manufactured more than 65 products sold by customers worldwide.

Click here for more.

 

  WHITEPAPERS & WEBINARS

WHITEPAPER - Large-Scale LNP Process Conversions

WHITEPAPER - Large-Scale LNP Process Conversions

Large-Scale LNP Process Conversions: The many hurdles of LNP scale-up and what to consider

Lipid nanoparticle (LNP) formulation development begins on a small scale, often with homemade or benchtop setups, using syringe pumps and easily accessible micro-mixing systems. Once …

WEBINAR - Challenges of Sustained Release Drug Delivery Devices

WEBINAR - Challenges of Sustained Release Drug Delivery Devices

Sustained release drug delivery is rapidly expanding across respiratory, ophthalmic, transdermal, and implantable applications, but translating products from development to manufacturing remains both complex and costly. Programs can stall due to material–drug compatibility issues, inconsistent release profiles, tooling-related variability, and …

WHITEPAPER - Streamlined Product Development Leveraging Pharmaceutical Classification Models

WHITEPAPER - Streamlined Product Development Leveraging Pharmaceutical Classification Models

A technology agnostic approach based on a fundamental understanding of API properties, a well-defined yet flexible target product profile, and a mindset for scalability and commercial relevance leads to success in formulation development and drug product design.

In this whitepaper, …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 30 – Formulation Development
October 7 – Prefilled Syringes
October 14 – Injection Devices
October 21 – Transdermal/Topical Delivery
October 28 – Formulation Development